Every material Form 8-K OneMedNet Corp has filed with the SEC since July 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
OneMedNet said year-to-date bookings reached approximately $18.76 million as of November 6, 2026, with $1.388 million converted to revenue through September 30, 2026. The company also reported that contracted demand is nearly 14 times its full-year 2025 bookings and that roughly half of its 2026 contracts come from new customers, while providing fourth-quarter 2026 guidance without figures in the filing text.
Year-to-date bookings: approximately $18.76 million as of November 6, 2026
Revenue converted from bookings: $1.388 million through September 30, 2026
Contracted demand is nearly 14 times full-year 2025 bookings
Roughly half of 2026 contracts are from new customers
OneMedNet said it expects preliminary third-quarter 2026 revenue of about $1 million, up 242% from the prior quarter and 465% from the year-earlier quarter. It also guided to fourth-quarter 2026 revenue of $12 million to $14 million, pending customer acceptance of delivered data by quarter-end. The third-quarter figures remain preliminary and may change before the Form 10-Q, expected by November 16, 2026.
Preliminary Q3 2026 revenue of about $1 million for the quarter ended September 30, 2026, up 242% from the prior quarter and 465% from Q3 2025.
Q4 2026 revenue guidance of about $12 million to $14 million, pending customer acceptance of delivered data by quarter-end.
Q3 results are preliminary and subject to adjustment; the Form 10-Q is expected by November 16, 2026.
OneMedNet Corporation received written notice from Nasdaq on October 13, 2026 that it has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had received a deficiency letter on April 14, 2026, and the closing bid price was at least $1.00 per share for 10 consecutive business days from September 29 through October 12, 2026. The filing shows the listing issue is resolved, which removes the risk of delisting over the bid price rule.
Nasdaq notified the company on October 13, 2026 that it regained compliance with Listing Rule 5550(a)(2).
The closing bid price was at least $1.00 per share for 10 consecutive business days, September 29 to October 12, 2026.
The original deficiency notice was received April 14, 2026, with a grace period to October 12, 2026.
The matter is now closed, according to the filing signed by CEO Aaron Green.
At its September 18, 2026 virtual annual meeting, OneMedNet stockholders elected three Class III directors, ratified WithumSmith+Brown as auditor for 2026, and approved a 1,000,000-share increase to the 2022 Equity Incentive Plan. They also approved a charter amendment allowing a reverse stock split at a ratio between 1-for-5 and 1-for-20, to be set by the board.
Stockholders approved adding 1,000,000 shares to the Amended and Restated 2022 Equity Incentive Plan, effective immediately.
Proposal 4 approved a reverse split ratio from 1-for-5 to 1-for-20, with the final ratio left to the Board of Directors; 41,068,200 votes were cast for it.
Dr. Kenneth Alleyne, Sherry Coonse McCraw and Dr. Jeffrey Yu were elected as Class III directors for terms expiring at the 2029 annual meeting.
Votes represented 70.57% of eligible votes, which met the quorum requirement.
OneMedNet's board set September 18, 2026 as the date for its 2026 Annual Meeting of Stockholders, with a record date of August 11, 2026. Because the meeting date moved more than 30 days from the anniversary of the December 17, 2025 meeting, the company updated its deadlines for stockholder proposals and director nominations to August 5, 2026. The filing is administrative and does not report financial results.
2026 Annual Meeting set for September 18, 2026; record date August 11, 2026
Stockholder proposals and director nominations must be received by August 5, 2026
Proposals must be sent to the Secretary at 6385 Old Shady Oak Road, Eden Prairie, Minnesota
Matters to be voted on will be detailed in a future definitive proxy statement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every OneMedNet Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →